65,437 trials
B-cell Childhood Acute Lymphoblastic Leukemia · L1 Childhood Acute Lymphoblastic Leukemia · L2 Childhood Acute Lymphoblastic Leukemia
Primary: Event Free Survival. EFS — 66.0 percentage of participants EFS at 3 yrs3
Depression · Back Pain
Primary: Proportion Responding Initially by Treatment Arm During 14 Weeks Post Randomization — 28; 28 Participants
Depression
Primary: Hamilton Depression Rating Scale. — 8.09 units on a scale
Elevated Body Mass Index
Primary: Part 1: Percent Change in Body Weight From Baseline to Week 12 — -5.51; 0.19; -6.55; 0.29 percent change — p=<0.001
Cystic Fibrosis
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) or Serious Adverse Events (SAEs) in Ivacaftor Arm — 117; 27 participants
Osteoporosis
Primary: All Study Sites--Length of Contracting Procedures — 3.4 Months
Advanced, Metastatic Breast Cancer
Primary: Progression Free Survival (PFS) by Investigator Assessment — NA; 14.7 months — p=0.00000329
Adult Alveolar Soft-part Sarcoma · Adult Angiosarcoma · Adult Epithelioid Sarcoma
Primary: Objective Tumor Response (Complete and Partial) — 2 Participants
Facial Injuries · Adipose Tissue
Primary: Volume — 0.576; 0.621 milliliters
Sporadic Inclusion Body Myositis
Primary: Change From Baseline in 6 Minute Walking Distance (6MWD) Test at Week 52 — 8.63; 9.63; -10.27; -8.96 meters — p=0.2210
Mucopolysaccharidosis · Hurler Syndrome · Hunter Syndrome
Primary: Number of Patients With Donor Derived Engraftment — 42 Participants
Lung Tumor
Primary: Total Morphine Consumption (mg) — 34.5; 44 mg
Alcohol Dependence
Primary: Clinical Response to Naltrexone, as Measured by a Reduction in the Percent Days of Heavy Drinking Days (as Defined by >5 Drinks/Day for Males; >4 for Females) During the…
Lymphoma
Primary: Disease-Free Survival — 34; 30; 28; 25 Participants
Critical Aortic Stenosis
Primary: Death — 84; 89; 55; 89 participants